CASTLE ROCK, Colo., Aug. 5, 2014 /PRNewswire/ -- Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its CE Marked APPY1™ Test, a rapid, multi-analyte assay for aiding in identifying children, adolescent and young adult patients that are at low risk for appendicitis, today announced it will present at the Canaccord Genuity 34th Annual Growth Conference, to be held August 13-14, 2014, at the Intercontinental Boston in Boston, MA.
Steve Lundy, President and CEO of Venaxis, will provide an overview of the Company's business during his scheduled presentation and will be available for one-on-one meetings with investors who are registered to attend the conference.
Event: Canaccord Genuity 34th Annual Growth Conference
Date: Thursday, August 14, 2014
Presentation Time: 1:00 pm (Eastern Time)
Location: Melbourne Room
The presentation will be webcast live. To access the webcast, please visit the investor relations section of the Venaxis website at http://ir.venaxis.com.
About Venaxis, Inc.
Venaxis, Inc. is an in vitro diagnostic company focused on the clinical development and commercialization of its CE Marked APPY1 Test, the Company's rapid, multi-analyte assay for appendicitis. This unique appendicitis test has projected high sensitivity and negative predictive value and is being developed to aid in the identification of patients at low risk for acute appendicitis, allowing for more conservative patient management. The APPY1 Test is being developed initially for pediatric, adolescent and young adult patients with abdominal pain, as this population is at
|SOURCE Venaxis, Inc.|
Copyright©2014 PR Newswire.
All rights reserved